Core Viewpoint - ADC Therapeutics SA is a global leader in antibody drug conjugates (ADCs) and will present at the J.P. Morgan Healthcare Conference on January 15, 2026 [1] Company Overview - ADC Therapeutics is focused on transforming treatment for patients through its portfolio, which includes ZYNLONTA (loncastuximab tesirine-lpyl) and an early-stage PSMA-targeting ADC [3] - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey, emphasizing innovation in ADC development from clinical to manufacturing and commercialization [5] Product Development - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [4] - The company is also developing a next-generation PSMA-targeting ADC that utilizes a differentiated exatecan-based payload with a novel hydrophilic linker [4]

Core Viewpoint - ADC Therapeutics SA has granted options to purchase 6,000 common shares to a new employee as an inducement for employment, aiming to motivate and reward high performance [1][2]. Group 1: Grant Details - The grant was approved by the Compensation Committee under the Company's Inducement Plan to encourage significant contributions to the Company's success [2]. - The options will vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the next three years, fully vesting by the fourth anniversary [3]. Group 2: Company Overview - ADC Therapeutics is a leader in antibody drug conjugates (ADCs), with a focus on transforming treatment for patients through its portfolio, including ZYNLONTA [4]. - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [5]. - The company is also developing a next-generation PSMA-targeting ADC with a differentiated payload and novel linker [5]. Group 3: Company Operations - ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London and New Jersey, focusing on innovation in ADC development from clinical to commercialization [6].

Core Viewpoint - Akari Therapeutics has made significant progress in 2025 towards developing best-in-class antibody drug conjugates (ADCs) with a novel payload, positioning the company for a pivotal year ahead in 2026 [1][12]. Group 1: Scientific Advancements - Akari has established a clear scientific roadmap focused on its proprietary PH1 payload, which is designed to overcome limitations of existing ADC payloads by directly killing cancer cells and engaging the immune system [2][4]. - The lead program, AKTX-101, is a Trop2 targeted ADC that utilizes the PH1 payload and has shown significant preclinical activity against various cancers, including pancreatic and prostate cancers [6][17]. - The partnership with WuXi XDC for GMP-grade clinical product manufacturing is a critical milestone that supports the upcoming Phase 1 clinical trials for AKTX-101 [4][7]. Group 2: Intellectual Property and Engagement - Akari has strengthened its intellectual property portfolio with new provisional patent filings related to the PH1 payload, enhancing the value of its ADC platform [8]. - Promising immuno-oncology data was presented at the Society for Immunotherapy Cancer (SITC), generating enthusiasm among researchers and scientists regarding the unique approach of splicing modulation via the PH1 payload [9]. Group 3: Operational and Financial Strategy - The company has taken steps to strengthen its operating model and capital discipline, enabling R&D milestones and key patent filings while reducing operating expenses post-merger [11]. - Akari is positioned to pursue additional financing and partnership opportunities with strategic investors and pharmaceutical companies, leveraging upcoming catalysts and milestones with AKTX-101 [11]. Group 4: Future Outlook - 2026 is anticipated to be a transformational year for Akari, with key milestones including the initiation of Phase 1 clinical studies, regulatory interactions with the FDA, and continued partnership discussions [12][15]. - The transition from a preclinical discovery company to a clinical-focused biotechnology player is expected to enhance visibility and investor interest [13][14].

Core Viewpoint - Akari Therapeutics has initiated GMP manufacturing activities for its lead ADC program, AKTX-101, in partnership with WuXi XDC, aiming to support clinical trials and advance cancer treatment options [1][2][4]. Group 1: Partnership and Manufacturing - Akari has selected WuXi XDC, a leading ADC contract development and manufacturing organization, for critical IND-enabling work to support clinical trials [2][4]. - The collaboration aims to leverage WuXi XDC's expertise in ADC development and manufacturing to produce high-quality GMP material for AKTX-101 [4][5]. Group 2: Product Development - AKTX-101 incorporates Akari's novel proprietary payload, PH1, which modulates RNA splicing and offers a differentiated approach to ADC design, potentially enhancing therapeutic impact [3][6]. - The manufacturing milestone is a significant step in advancing Akari's pipeline of differentiated ADC therapies, which aim to improve outcomes for cancer patients [5][6]. Group 3: Future Plans - The company plans to initiate a Phase 1 first-in-human clinical trial for AKTX-101 in approximately 12 months, pending regulatory clearance [4][5]. - Akari's innovative ADC design and payload technology, combined with WuXi's manufacturing capabilities, are expected to lay the groundwork for multiple ADC programs utilizing the PH1 payload [4][6].

Core Viewpoint - Akari Therapeutics has announced a definitive agreement for the issuance and sale of approximately 12.6 million American Depositary Shares (ADSs) and unregistered warrants, with significant participation from its Directors, Officers, and Executive Management, aimed at supporting its oncology drug development initiatives and improving its capital structure [1][4][6]. Group 1: Offering Details - The offering includes 10,043,774 ADSs in a registered direct offering priced at $0.3883 per ADS, along with unregistered Series G warrants [3]. - A concurrent private placement will issue unregistered pre-funded warrants for 2,563,713 ADSs at a combined price of $0.4041 per ADS [3]. - The gross proceeds from the offering are expected to be around $5 million, with over $1 million coming from new cash investments by the Company's Directors, Officers, and Executive Management [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for ongoing research and development, working capital, and general corporate purposes [4]. Group 3: Debt Conversion - Existing note holders have agreed to convert approximately $2.5 million of the Company's outstanding debt into unregistered pre-funded warrants and warrants to purchase 6,409,410 ADSs at a combined exchange price of $0.4041 per ADS [5]. Group 4: Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs), with its lead candidate AKTX-101 targeting the Trop2 receptor on cancer cells [10]. - The novel payload PH1 is designed to disrupt RNA splicing within cancer cells, showing significant activity and prolonged survival in preclinical studies compared to traditional ADCs [10].

Core Insights - Akari Therapeutics is advancing a new class of immuno-oncology antibody drug conjugates (ADCs) utilizing a novel PH1 payload designed to target and disrupt the spliceosome, showing promising preclinical efficacy and safety profiles [3][4] - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and is set to enter IND-enabling studies with plans for clinical trials in Q4 2026 [3][4] Company Overview - Akari Therapeutics specializes in developing next-generation spliceosome payload ADCs, differentiating itself from traditional ADCs that use tubulin inhibitors and DNA damaging agents [4] - The PH1 payload is a spliceosome modulator that disrupts RNA splicing in cancer cells, leading to cancer cell death and activation of immune responses [4] Product Development - AKTX-101 has demonstrated significant activity and prolonged survival in preclinical studies compared to traditional ADCs, with potential for synergy with checkpoint inhibitors [4] - The company is generating validating data on the PH1 payload to advance AKTX-101 and explore other undisclosed targets [4]

Core Insights - Akari Therapeutics is presenting new data on its novel antibody drug conjugate (ADC) payload, PH1, at the 40th Annual SITC Meeting, highlighting its immune mechanism-of-action and potential in oncology treatment [1][2]. Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload ADCs, with its lead candidate, AKTX-101, targeting the Trop2 receptor on cancer cells [5]. - The PH1 payload is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, showing preclinical efficacy in inducing cancer cell death and activating immune responses [5]. Research Findings - The abstract presented at SITC indicates that the PH1 ADC, in combination with anti-PD-1, resulted in a higher rate of complete tumor regressions compared to a first-in-class ADC with a microtubule inhibitor payload [2]. - The immune response stimulated by the PH1 ADC involves neoantigen activation, antigen-presenting cells, and T-cell activation, leading to enhanced therapeutic potential [2]. Presentation Details - The oral and poster presentations will provide further insights into the findings, with specific sessions scheduled for November 7 and November 9, 2025 [3][4].

Core Insights - Akari Therapeutics is presenting data on its novel antibody drug conjugate (ADC) payload, PH1, at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting, highlighting its immune mechanism-of-action and potential in oncology [1][2] Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload ADCs, with its lead candidate, AKTX-101, targeting the Trop2 receptor on cancer cells [5][6] - The PH1 payload is designed to disrupt RNA splicing within cancer cells, showing preclinical efficacy in inducing cancer cell death and activating immune cells [5][6] Research Findings - The abstract presented at SITC indicates that the PH1 ADC, in combination with anti-PD-1, resulted in a higher rate of complete tumor regressions compared to a first-in-class ADC with a microtubule inhibitor payload [2] - The immune response stimulated by the PH1 ADC is attributed to neoantigen activation, which enhances the activity of antigen-presenting cells, B, and T-cells [2] - Notably, the combination of PH1 ADC and anti-PD-1 expanded the population of gamma-delta T cells, which are effective in tumor killing [2] Presentation Details - The oral and poster presentations will take place on November 7 and 9, 2025, at the Gaylord National Resort and Convention Center, with specific times and locations provided for attendees [3][4]

Core Insights - ADC Therapeutics SA is a global leader in antibody drug conjugates (ADCs) and will host a conference call on November 10, 2025, to report Q3 2025 financial results and operational updates [1][2]. Company Overview - ADC Therapeutics is focused on transforming treatment for patients through its portfolio, including ZYNLONTA (loncastuximab tesirine-lpyl) and an early-stage PSMA-targeting ADC [3]. - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey, emphasizing innovation in ADC development from clinical to manufacturing and commercialization [5]. Product Development - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [4]. - ADC Therapeutics is also developing a next-generation PSMA-targeting ADC that utilizes a differentiated exatecan-based payload with a novel hydrophilic linker [4].

Core Insights - Akari Therapeutics has launched a new platform called CEO Corner, aimed at providing deeper insights into the company's press releases, corporate developments, and pipeline progress [2][3] - The CEO Corner will allow stakeholders to ask questions and suggest topics for future discussions, enhancing engagement and transparency [1][2] Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) for oncology applications [4] - The company's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver a novel PH1 payload directly into tumors [4] - PH1 is designed to modulate RNA splicing within cancer cells, leading to cancer cell death and activation of immune responses, showing significant activity in preclinical studies compared to traditional ADCs [4] Product Development - AKTX-101 has demonstrated prolonged survival in preclinical models, both as a single agent and in combination with checkpoint inhibitors, indicating its potential for synergistic effects [4] - The company is actively generating validating data on the PH1 payload to further advance AKTX-101 and explore other undisclosed targets [4]